Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06310512
Other study ID # ANZHEN HOSPITOL-LY-04
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 1, 2024
Est. completion date June 30, 2026

Study information

Verified date March 2024
Source Beijing Anzhen Hospital
Contact JuanJuan Wei, MS
Phone 01064456609
Email weijj2005@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this Randomized Controlled Trial is to carry out in adult patients with primary hypertension whose blood pressure control is not up to standard. The main question it aims to answer are: To explore the effect of pharmacists' implementation of "the medication therapy management pathway in hypertensive patients"on the patients with hypertension. Participants will receive structured drug treatment management at the first diagnosis. During on-site follow-up in the first, third and sixth months, as well as telephone follow-up in the second week, second and fourth months, patients will be evaluated, corresponding information will be collected and possible interventions will be taken. Researchers will compare the non intervention group to see if patients' blood pressure will also be reduced without intervention.


Description:

The purpose of this study is to explore the effectiveness, safety, and cost-effectiveness of pharmacists implementing the Drug Treatment Management Pathway in the treatment of hypertension patients. This trial is a prospective, multi-center, randomized, controlled study. We plan to enroll 420 patients with primary hypertension who are over 18 years old and whose blood pressure control is not up to standard. Qualified participants who meet the inclusion and exclusion criteria were randomly divided into an intervention group of 280 cases and a non intervention group of 140 cases in a 2:1 ratio.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 420
Est. completion date June 30, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years old, male or female; 2. Outpatients diagnosed with primary hypertension who have not received treatment or are receiving antihypertensive medication; 3. Mild to moderate hypertensive patients with substandard blood pressure: home blood pressure >140/90 mmHg at least once in the last month or more, and the average sitting blood pressure in the clinic on the day of enrollment is >140/90 mmHg; 4. Expected survival > 12 months; 5. Voluntary participation in the trial and signing the informed consent form. Exclusion Criteria: 1. Severe hypertension (mean SBP =180mmHg, or mean DBP =110mmHg), hypertensive emergency or hypertensive sub-emergency (systolic blood pressure >180 mmHg or diastolic blood pressure >120 mmHg); 2. Have a history or diagnosis of secondary hypertension, including but not limited to the following: renal hypertension, renal vascular hypertension, aortic stenosis, pheochromocytoma, Cushing's syndrome, cystic nephropathy, etc., but drug-induced hypertension is not an exclusion criterion; 3. Patients in the acute stage of the disease requiring emergency medical consultation; 4. patients with mental disorder, hearing impairment, intellectual disability, aphasia, etc., resulting in the inability to communicate or to comply with the study agreement 5. Patients with tumors; 6. Any other reasons that the investigator considers unsuitable for participation in the clinical trial that may affect the efficacy and safety evaluation of the study (including, but not limited to, the investigator's judgment that the subject lives far away and cannot be followed up as scheduled).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Structured drug therapy management
Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment

Locations

Country Name City State
China Beijing Anzhen Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Anzhen Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary systolic blood pressure Change from baseline in mean seated systolic blood pressure at 6 months 6 months
Secondary diastolic blood pressure Changes from baseline in mean seated diastolic blood pressure at 6 months 6 months
Secondary Change from baseline in mean sitting systolic blood pressure at 3 months Change from baseline in mean sitting systolic blood pressure at 3 months 3 months
Secondary Change from baseline in number of medication-related problems (MRP) at 6 months Change from baseline in number of medication-related problems (MRP) at 6 months 6 months
Secondary Average number of medication-related problems (MRP) resolved after 6 months Average number of medication-related problems (MRP) resolved after 6 months 6 months
Secondary The compliance rate of blood pressure after 6 months The compliance rate of blood pressure after 6 months 6 months
Secondary Effective rate of blood pressure lowering after 6 months Effective rate of blood pressure lowering after 6 months 6 months
Secondary Time to BP Attainment in Intervention and Non-Intervention Groups Time to BP Attainment in Intervention and Non-Intervention Groups From the date of enrollment to the date when the patient's first blood pressure meets the standard, the evaluation is conducted up to 6 months
Secondary Changes from baseline in adherence scores at 6 months,the General Medication Compliance Scale (GMAS) was used. The General Medication Compliance Scale (GMAS) was used, with a maximum score of 33 and a minimum score of 0. The higher the score, the higher the patient's compliance. 6 months
Secondary Economic indicators,mainly including the cost of implementing intervention measures and the impact of intervention measures on patient diagnosis and treatment costs The implementation costs of intervention measures mainly include the development, installation, and annual maintenance costs of Interactive Network Response System (IWRS), labor costs of intervention measures, material costs incurred during the intervention process, multi center collaboration costs, and other costs incurred due to the intervention measures. Intervention measures have an impact on patient diagnosis and treatment costs, mainly including an increase in per visit outpatient expenses and medication costs. 6 months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A